Have courage in using nasal potential difference for diagnostic decisions and clinical research

Measurement of the nasal potential difference (NPD) was introduced in 1995 by Mike Knowles and colleagues to quantify cystic fibrosis transmembrane conductance regulator (CFTR) function at the respiratory epithelia and assess CFTR modulation [1]. Five years later, Michael Wilschanski and colleagues described the effect of gentamicin on the NPD in cystic fibrosis (CF) patients with stop mutations [2] and the use of NPD as a diagnostic tool in atypical CF [3]. It took time and effort, from single center experiences to international harmonized protocols, to overcome differences in equipment, perfusion protocols, quality control, over-reading, and analysis [4-5].

Source: Journal of Cystic Fibrosis - June 25, 2020 Category: Respiratory Medicine Authors: Lutz Naehrlich Source Type: research